Fiocruz researchers call for genomic sovereignty to ensure health equity in Latin America

Emerging challenge to the current asymmetric global health system where developed nations extract genetic data from developing regions but control resulting technologies. Latin American bloc-building (CELAC, Mercosur, CARICOM) seeks to consolidate bargaining power and link data sharing to technology transfer, intellectual property participation, and capacity building—redistributing benefits from unilateral to reciprocal arrangements.

Similar to OPEC's resource nationalism in the 1970s and contemporary debates over digital sovereignty and data colonialism; reflects post-colonial assertions of control over biological resources (echoing Nagoya Protocol negotiations on biodiversity benefit-sharing).

Latin American and Caribbean consumers could benefit from faster access to vaccines, diagnostics, and treatments developed from regional genetic data, while potentially facing higher costs if technology transfer agreements increase local production expenses. Improved regional capacity may enhance healthcare equity and reduce dependency on external suppliers.

Regional blocs (CELAC, Mercosur, CARICOM) may establish new frameworks requiring technology transfer and IP participation as conditions for genetic data sharing. This could reshape global biotech partnerships, create bilateral negotiation leverage, and influence WHO and PAHO policies on genetic data governance. May trigger counter-policies from developed nations and pharmaceutical companies.